18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
暂无分享,去创建一个
Roger Slavik | Michael S Hofman | Amar U Kishan | Bital Savir-Baruch | Matthias Eiber | Thomas A Hope | Christoph Rischpler | David Elashoff | Hossein Jadvar | Johannes Czernin | A. Kishan | D. Elashoff | C. Nanni | H. Jadvar | J. Czernin | M. Hofman | R. Reiter | C. Rischpler | T. Hope | K. Nguyen | M. Eiber | M. Rettig | W. Fendler | J. Calais | J. Gartmann | R. Slavik | T. Grogan | Magnus Dahlbom | Tore Bach-Gansmo | Jeremie Calais | Francesco Ceci | Robert E Reiter | Wolfgang P Fendler | Cristina Nanni | Magnus Dahlbom | Tristan Grogan | Jeannine Gartmann | Kathleen Nguyen | Vincent Lok | Matthew B Rettig | V. Lok | B. Savir-Baruch | T. Bach‐Gansmo | F. Ceci
[1] Frode Willoch,et al. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer , 2017, The Journal of urology.
[2] Ephraim E. Parent,et al. ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer. , 2018, Clinical nuclear medicine.
[3] R. Hicks,et al. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. , 2018, Radiographics : a review publication of the Radiological Society of North America, Inc.
[4] C. Cordon-Cardo,et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] M. Schwaiger,et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.
[6] Slave Trajanoski,et al. Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.
[7] P. Carroll,et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.
[8] R. Karnes,et al. Approach to Oligometastatic Prostate Cancer. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[9] Chong Hyun Suh,et al. Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. , 2018, European urology.
[10] E. Goetghebeur,et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Ferrari,et al. 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[12] U. Haberkorn,et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.
[13] Qian Wang,et al. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. , 2011, Cancer research.
[14] Bernd J. Krause,et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[15] T. Holland-Letz,et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[16] Pawan K Gupta,et al. 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study , 2017, The Journal of Nuclear Medicine.
[17] P. Carroll,et al. Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology , 2018, The Journal of Nuclear Medicine.
[18] L. Kostakoglu,et al. Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using 18F-Fluciclovine PET/CT , 2017, The Journal of Nuclear Medicine.
[19] Daniel W. D. West,et al. Characterisation of L-Type Amino Acid Transporter 1 (LAT1) Expression in Human Skeletal Muscle by Immunofluorescent Microscopy , 2017, Nutrients.
[20] D. Schuster,et al. Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[21] D. Mankoff,et al. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial , 2019, The Journal of urology.
[22] Matthias Eiber,et al. 68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging , 2018, The Journal of Nuclear Medicine.
[23] H. Kauczor,et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[24] Osman Ratib,et al. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] A. Wall,et al. The clinical safety, biodistribution and internal radiation dosimetry of [18F]fluciclovine in healthy adult volunteers , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[26] S. Fanti,et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.
[27] Frederik L. Giesel,et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT , 2017, The Journal of Nuclear Medicine.
[28] K. Herrmann,et al. Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence , 2017, The Journal of Nuclear Medicine.